Barry M Berger

Summary

Publications

  1. ncbi USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing
    Barry M Berger
    EXACT Sciences Corporation, 441 Charmany Dr, Madison, WI 553719 E mail
    Am J Manag Care 22:e77-81. 2016
  2. ncbi Colon cancer-associated DNA mutations: marker selection for the detection of proximal colon cancer
    Barry M Berger
    Department of dagger Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Diagn Mol Pathol 12:187-92. 2003
  3. ncbi Gene mutations in advanced colonic polyps: potential marker selection for stool-based mutated human DNA assays for colon cancer screening
    Barry M Berger
    EXACT Sciences Corporation, Maynard, MA, USA
    Clin Colorectal Cancer 3:180-5. 2003
  4. ncbi Colorectal cancer screening using stool DNA analysis in clinical practice: early clinical experience with respect to patient acceptance and colonoscopic follow-up of abnormal tests
    Barry M Berger
    Laboratory Medicine, EXACT Sciences Corporation, Marlborough, MA 01752, USA
    Clin Colorectal Cancer 5:338-43. 2006
  5. doi Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates
    Barry M Berger
    EXACT Sciences Corporation, Madison, WI, USA
    Pathology 44:80-8. 2012
  6. doi Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness
    Barry M Berger
    EXACT Sciences Corporation, Madison, WI Electronic address
    Clin Colorectal Cancer 15:e65-74. 2016
  7. pmc Multitarget stool DNA for colorectal cancer screening: A review and commentary on the United States Preventive Services Draft Guidelines
    Barry M Berger
    Barry M Berger, Medical Affairs, EXACT Sciences Corporation, Madison, WI 53719, United States
    World J Gastrointest Oncol 8:450-8. 2016
  8. doi Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia
    Graham P Lidgard
    EXACT Sciences Corporation, Madison, Wisconsin
    Clin Gastroenterol Hepatol 11:1313-8. 2013

Collaborators

  • Paul C Schroy
  • Bernard Levin
  • Tuan A Dinh
  • Graham P Lidgard
  • MICHAEL J DOMANICO
  • Julie A Simonson
  • Zubin D Gagrat
  • Mary Devens
  • William R Taylor
  • Hatim Allawi
  • Tracy C Yab
  • Rebecca L Oldham-Haltom
  • Janelle J Bruinsma
  • Keith D Fourrier
  • David A Ahlquist
  • James Light
  • Russell I Heigh

Detail Information

Publications8

  1. ncbi USPSTF colorectal cancer screening guidelines: an extended look at multi-year interval testing
    Barry M Berger
    EXACT Sciences Corporation, 441 Charmany Dr, Madison, WI 553719 E mail
    Am J Manag Care 22:e77-81. 2016
    ..We demonstrate that USPSTF modeling includes an embedded sensitivity analysis of less frequent than annual test adherence, which provides support for the inclusion of mt-sDNA 3y as a recommended test...
  2. ncbi Colon cancer-associated DNA mutations: marker selection for the detection of proximal colon cancer
    Barry M Berger
    Department of dagger Pathology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA, USA
    Diagn Mol Pathol 12:187-92. 2003
    ..The adjunctive use of stool DNA mutation analysis using this marker panel in FS CRC screening programs may significantly increase the detection of proximal CRC...
  3. ncbi Gene mutations in advanced colonic polyps: potential marker selection for stool-based mutated human DNA assays for colon cancer screening
    Barry M Berger
    EXACT Sciences Corporation, Maynard, MA, USA
    Clin Colorectal Cancer 3:180-5. 2003
    ..Stool DNA based assays that can identify these mutations may significantly increase the identification of patients with potentially premalignant ACPs for evaluation and treatment by colonoscopy...
  4. ncbi Colorectal cancer screening using stool DNA analysis in clinical practice: early clinical experience with respect to patient acceptance and colonoscopic follow-up of abnormal tests
    Barry M Berger
    Laboratory Medicine, EXACT Sciences Corporation, Marlborough, MA 01752, USA
    Clin Colorectal Cancer 5:338-43. 2006
    ..The main objectives of this study were to examine patients' screening experiences with stool DNA testing in routine clinical practice and the results of diagnostic colonoscopy in patients with an antecedent abnormal stool DNA test...
  5. doi Stool DNA screening for colorectal neoplasia: biological and technical basis for high detection rates
    Barry M Berger
    EXACT Sciences Corporation, Madison, WI, USA
    Pathology 44:80-8. 2012
    ..This review discusses the biological basis, key technical advances, and recent clinical performance validation of stool DNA testing...
  6. doi Screening for Colorectal Cancer Using a Multitarget Stool DNA Test: Modeling the Effect of the Intertest Interval on Clinical Effectiveness
    Barry M Berger
    EXACT Sciences Corporation, Madison, WI Electronic address
    Clin Colorectal Cancer 15:e65-74. 2016
    ..We used clinical effectiveness modeling to project decreases in CRC incidence and related mortality associated with mt-sDNA screening to help inform interval setting...
  7. pmc Multitarget stool DNA for colorectal cancer screening: A review and commentary on the United States Preventive Services Draft Guidelines
    Barry M Berger
    Barry M Berger, Medical Affairs, EXACT Sciences Corporation, Madison, WI 53719, United States
    World J Gastrointest Oncol 8:450-8. 2016
    ....
  8. doi Clinical performance of an automated stool DNA assay for detection of colorectal neoplasia
    Graham P Lidgard
    EXACT Sciences Corporation, Madison, Wisconsin
    Clin Gastroenterol Hepatol 11:1313-8. 2013
    ..We optimized an automated sDNA assay and evaluated its clinical performance...